Nicholas Likely to Drop Chikungunya Research (India)
This article was originally published in PharmAsia News
Executive Summary
Nicholas Piramal India (NPIL) is expected to withdraw its proposal for a joint venture drug discovery research program with Laboratories Pierre Fabre of France due to the slow regulatory process. The research program was slated to develop the world's first vaccine for chikungunya, which has evolved into an epidemic after spreading throughout southern India and Maharashtra over the last two years. But the Central Drug Control Authority has yet to authorize the project. "We will have to drop the drug research plans for chikungunya, since the Drug Controller General of India (DCGI) is yet to sanction the project," said NPLI Director of Strategic Alliances Swati Piramal. In light of the delays, Piramal explained that there was little else the company could do. "It is almost six months since we applied." The new drugs require the DGCI's approval before they can enter the Indian market. (Click here for more
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.